All healthy subjects have been treated in Hansa Medicals´ Phase I-study with IdeS
All healthy subjects have been recruited and dosed in Hansa Medicals’ Phase I-study with drug candidate IdeS. The results are anticipated for release in early 2014.The Phase I-study is a double blind, randomized study in healthy subjects administered intravenous single doses of IdeS or placebo. Study objectives are to study safety, tolerability, pharmacokinetics and IgG-cleaving effect. The aim is to initiate a Phase II-study with sensitized transplantation patients in 2014. ”The dosing in the Phase I-study with IdeS is now completed. We look forward to communicate the results from the